Opportunity

Federal Register #2026-07367

FDA Classifies Orthopedic Manual Surgical Instruments and Reclassifies Bone Growth Stimulators

Buyer

Food and Drug Administration

Posted

April 16, 2026

Identifier

2026-07367

NAICS

339112, 334510, 339113

This summary covers the FDA's final rule classifying certain orthopedic medical devices: - Government Buyer: - Food and Drug Administration (FDA), Center for Devices and Radiological Health - Devices Classified: - Manual surgical instrument for appropriate patient selection for orthopedic implant (part number 888.4510) - Used to measure anatomical features to determine patient suitability for orthopedic implants - Special controls required: - Validation of technical specifications and measurement processes - Biocompatibility of patient-contacting components - Labeling with validated implant identification and reprocessing instructions - Non-invasive bone growth stimulator - Device intended to promote osteogenesis for fracture fixation, spinal fusion, or treatment of nonunions/failed fusions - Reclassified from Class III to Class II, subject to premarket notification - OEMs and Vendors: - No specific OEMs or vendors are named; this is a regulatory classification, not a procurement - Unique Requirements: - Devices must meet special controls for safety and effectiveness, including technical validation, biocompatibility, and specific labeling - The rule aims to reduce regulatory burden and improve patient access to innovative orthopedic devices

Description

The Food and Drug Administration (FDA) is classifying the manual surgical instrument for appropriate patient selection for orthopedic implant into class II (special controls). This classification provides reasonable assurance of safety and effectiveness for the device, which is used to measure anatomical features to determine patient suitability for orthopedic implants. The special controls include technical specifications, validation of measurement processes, biocompatibility of patient-contacting components, and specific labeling requirements. This action aims to enhance patient access to innovative devices by reducing regulatory burdens while ensuring safety.

View original listing